| 1 | solutions esperante development bv | | | | | | | 3 | 1.31% |
| 2 | nordic pharma sever pharma | | | | | | | 2 | 0.87% |
| 3 | esperante development bv contact | | | | | | | 2 | 0.87% |
| 4 | about us esg topics | | | | | | | 2 | 0.87% |
| 5 | us esg topics our | | | | | | | 2 | 0.87% |
| 6 | esg topics our team | | | | | | | 2 | 0.87% |
| 7 | topics our team company | | | | | | | 2 | 0.87% |
| 8 | our team company profiles | | | | | | | 2 | 0.87% |
| 9 | team company profiles nordic | | | | | | | 2 | 0.87% |
| 10 | company profiles nordic pharma | | | | | | | 2 | 0.87% |
| 11 | profiles nordic pharma sever | | | | | | | 2 | 0.87% |
| 12 | of patients first built | | | | | | | 1 | 0.44% |
| 13 | needs of patients first | | | | | | | 1 | 0.44% |
| 14 | the needs of patients | | | | | | | 1 | 0.44% |
| 15 | put the needs of | | | | | | | 1 | 0.44% |
| 16 | our company about us | | | | | | | 1 | 0.44% |
| 17 | to put the needs | | | | | | | 1 | 0.44% |
| 18 | continually to put the | | | | | | | 1 | 0.44% |
| 19 | work continually to put | | | | | | | 1 | 0.44% |
| 20 | first built on success | | | | | | | 1 | 0.44% |
| 21 | patients first built on | | | | | | | 1 | 0.44% |
| 22 | company we recognize that | | | | | | | 1 | 0.44% |
| 23 | established in 2019 as | | | | | | | 1 | 0.44% |
| 24 | in 2019 as a | | | | | | | 1 | 0.44% |
| 25 | 2019 as a holding | | | | | | | 1 | 0.44% |
| 26 | as a holding company | | | | | | | 1 | 0.44% |
| 27 | a holding company we | | | | | | | 1 | 0.44% |
| 28 | holding company we recognize | | | | | | | 1 | 0.44% |
| 29 | across the globe these | | | | | | | 1 | 0.44% |
| 30 | we recognize that our | | | | | | | 1 | 0.44% |
| 31 | recognize that our network | | | | | | | 1 | 0.44% |
| 32 | of companies encompasses a | | | | | | | 1 | 0.44% |
| 33 | the globe these companies | | | | | | | 1 | 0.44% |
| 34 | achieve remarkable outcomes located | | | | | | 1 | 0.44% |
| 35 | markets across the globe | | | | | | | 1 | 0.44% |
| 36 | rich talent and full | | | | | | | 1 | 0.44% |
| 37 | their own specialist focus | | | | | | | 1 | 0.44% |
| 38 | own specialist focus this | | | | | | | 1 | 0.44% |
| 39 | specialist focus this collaborative | | | | | | | 1 | 0.44% |
| 40 | focus this collaborative approach | | | | | | | 1 | 0.44% |